• Lemuel A Brown, Steve D Guzman, and Susan V Brooks.
• Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan.
• Transl Res. 2020 Jul 1; 221: 445744-57.

AbstractThe age-associated decline in muscle mass has become synonymous with physical frailty among the elderly due to its major contribution in reduced muscle function. Alterations in protein and redox homeostasis along with chronic inflammation, denervation, and hormonal dysregulation are all hallmarks of muscle wasting and lead to clinical sarcopenia in older adults. Reduction in skeletal muscle mass has been observed and reported in the scientific literature for nearly 2 centuries; however, identification and careful examination of molecular mediators of age-related muscle atrophy have only been possible for roughly 3 decades. Here we review molecular targets of recent interest in age-related muscle atrophy and briefly discuss emerging small molecule therapeutic treatments for muscle wasting in sarcopenic susceptible populations.Copyright © 2020 Elsevier Inc. All rights reserved.

9 keywords...

hide…